Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	22.16B +7.1%
Revenue (ttm)	2.15B +22.6%
Net Income	794.27M +27.1%
EPS	0.13 +26.4%
Shares Out	n/a
PE Ratio	27.90
Forward PE	25.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109
Open	5.160
Previous Close	3.825
Day's Range	3.825 - 5.160
52-Week Range	3.544 - 5.200
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,347
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2025, HNSPF's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error